1. 1

    Posted on: February 2, 2017 - Journal articles

    Safety of a killed oral cholera vaccine (Shanchol) in pregnant women in Malawi: an observational cohort study

    Article published in The Lancet on 2-February-2017 by Ali, Mohammad et al. ABSTRACT Pregnancy increases the risk of harmful effects from cholera for both mothers and their fetuses. A killed oral cholera vaccine, Shanchol (Shantha Biotechnics, Hydrabad, ...

  2. 2

    Posted on: October 17, 2016 - Journal articles

    Effectiveness of one dose of oral cholera vaccine in response to an outbreak: a case-cohort study

    Article published in The Lancet on 17-October-2016 by Azman, Andrew S. et al.  ABSTRACT Oral cholera vaccines represent a new effective tool to fight cholera and are licensed as two-dose regimens with 2–4 weeks between doses. Evidence from previous ...

  3. 3

    Posted on: May 18, 2016 - Journal articles

    The oral cholera vaccine Shanchol™ when stored at elevated temperatures maintains the safety and immunogenicity profile in Bangladeshi participants.

    Article published in Vaccine on 18-March-2016 by Saha A et al.  ABSTRACT BACKGROUND: The oral cholera vaccine (OCV), Shanchol™ has shown protective efficacy lasting up to 5 years, however, requirement for a cold chain limits its use in resource poor ...

  4. 4

    Posted on: May 5, 2016 - Journal articles

    Efficacy of a Single-Dose, Inactivated Oral Cholera Vaccine in Bangladesh

    Article published in The New England Journal of Medicine on 5-May-2016 by Qadri F. et al.   ABSTRACT BACKGROUND:  A single-dose regimen of the current killed oral cholera vaccines that have been prequalified by the World Health Organization would make ...

  5. 5

    Posted on: August 25, 2015 - Journal articles

    The Impact of a One-Dose versus Two-Dose Oral Cholera Vaccine Regimen in Outbreak Settings: A Modeling Study

    Article published in PLOS Medicine on 25-August-2015 by Azman AS et al. ABSTRACT Background: In 2013, a stockpile of oral cholera vaccine (OCV) was created for use in outbreak response, but vaccine availability remains severely limited. Innovative ...

  6. 6

    Posted on: March 12, 2015 - Journal articles

    Flexibility of Oral Cholera Vaccine Dosing—A Randomized Controlled Trial Measuring Immune Responses Following Alternative Vaccination Schedules in a Cholera Hyper-Endemic Zone

    Article published by PLOS Neglected Tropical Diseases on 12-March-2015 by Kanungo S. et al. ABSTRACT Background: A bivalent killed whole cell oral cholera vaccine has been found to be safe and efficacious for five years in the cholera endemic setting of ...

  7. 7

    Posted on: February 25, 2015 - Journal articles

    Immunogenicity of the Bivalent Oral Cholera Vaccine Shanchol in Haitian Adults With HIV Infection

    Article published in The Journal of Infectious Diseases on 25-February-2015 by Ivers LC et al. ABSTRACT We evaluated immune responses following bivalent oral cholera vaccination (Shanchol [Shantha Biotechnics]; BivWC) in a cohort of 25 human ...

  8. 8

    Posted on: August 23, 2014 -

    Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis

    Article published in The Lancet on 02-Jul-2005 by Ali M et al. BACKGROUND: Decisions about the use of killed oral cholera vaccines, which confer moderate levels of direct protection to vaccinees, can depend on whether the vaccines also provide indirect ...

  9. 9

    Posted on: August 23, 2014 -

    Effectiveness of mass oral cholera vaccination in Beira, Mozambique

    Article published in the New England Journal of Medicine on 24-Feb-2005 by Lucas ME et al. BACKGROUND: New-generation, orally administered cholera vaccines offer the promise of improved control of cholera in sub-Saharan Africa. However, the high ...

  10. 10

    Posted on: August 23, 2014 -

    Two-year study of the protective efficacy of the oral whole cell plus recombinant B subunit cholera vaccine in Peru

    Article published in the Journal of Infectious Diseases on 18-May-2000 by Taylor DN et al. ABSTRACT: The protective efficacy of an oral inactivated whole cell Vibrio cholerae plus recombinant B subunit cholera vaccine was determined against El Tor cholera ...